DGICB
Donegal Group Inc.
There isn't enough reported data to score DGICB yet.
MS
Morgan Stanley
MS's fundamentals are strong: revenue grew 16% and earnings per share grew 29%. At 15x earnings, it's trading in line with its usual 14x. Analysts expect earnings growth.
DGICB Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| N/A | |
| N/A |
DGICB's revenue and profitability are currently stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like DGICB.
MS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
MS's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like MS.
DGICB PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 8.1x | $8.91 | -68% |
| Current | 11x | $27.91 | — |
| Fair | 13x | $13.85 | -50% |
| Forward | 15x | $27.91 | — |
| Expensive | 66x | $72.34 | +159% |
Historical ranges are pointers, not guarantees.
DGICB's PE is 11x, but its earnings don't support one, so it isn't a reliable read right now.
MS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $134 | -29% |
| Fair | 14x | $178 | -5.7% |
| Forward | 14x | $189 | — |
| Current | 15x | $189 | — |
| Expensive | 18x | $223 | +18% |
Historical ranges are pointers, not guarantees.
MS has the edge over DGICB in the historical PE scenario, which offers more potential upside but is not a forecast.
DGICB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Stable | |
| Improving | |
| Limited | |
| High |
Analysts expect DGICB's profitability to improve, with its earnings and revenue holding steady.
MS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
MS has the edge over DGICB on the outlook, with more favorable earnings and revenue expectations.
DGICB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.92 | +74% |
| Q3 2021 | $1.10 | -38% |
| Q2 2021 | $1.68 | +7% |
| Q1 2021 | $1.98 | +106% |
| Q4 2020 | $1.77 | +7.9% |
MS has the stronger earnings trend. Trailing diluted EPS is down 38% for DGICB versus MS up 29%.
MS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.39 | +6.3% |
| Q3 2026 | $12.60 | +29% |
| Q2 2026 | $12.37 | +40% |
| Q1 2026 | $11.04 | +29% |
| Q4 2025 | $10.21 | +28% |
| Q3 2025 | $9.76 | +48% |
| Q2 2025 | $8.84 | +45% |
| Q1 2025 | $8.53 | +55% |
| Q4 2024 | $7.95 | +53% |
MS's earnings per share have climbed steadily: $12.60 over the past year, up 29% from the year before, and higher year over year for 10 quarters in a row.
DGICB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $237.7M | -3.4% |
| Q2 2026 | $241.1M | -2.4% |
| Q1 2026 | $236M | -3.7% |
| Q4 2025 | $240.1M | -3.9% |
| Q3 2025 | $245.9M | -2.3% |
| Q2 2025 | $247.1M | +0.2% |
| Q1 2025 | $245.2M | +1.7% |
| Q4 2024 | $250M | +4.4% |
DGICB's revenue grew through 2023 and has held roughly level since: $238M last quarter, down 3.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.3% | -0.9 points |
| Q2 2026 | 11% | +3.2 points |
| Q1 2026 | 6% | -6.7 points |
| Q4 2025 | 8.7% | -3.1 points |
| Q3 2025 | 10% | +2.1 points |
| Q2 2025 | 8.3% | +6.2 points |
| Q1 2025 | 13% | +9.7 points |
| Q4 2024 | 12% | +13 points |
DGICB's operating margin was 9.3% last quarter, down 0.9 points from the same quarter a year ago.
MS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.3B | +12% |
| Q2 2026 | $21.3B | +27% |
| Q1 2026 | $20.6B | +16% |
| Q4 2025 | $17.9B | +10% |
| Q3 2025 | $18.2B | +18% |
| Q2 2025 | $16.8B | +12% |
| Q1 2025 | $17.7B | +17% |
| Q4 2024 | $16.2B | +26% |
MS has the edge over DGICB on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -1.2 points |
| Q2 2026 | 34% | +6.9 points |
| Q1 2026 | 34% | +2.8 points |
| Q4 2025 | 32% | +2 points |
| Q3 2025 | 33% | +5.6 points |
| Q2 2025 | 28% | +0.4 points |
| Q1 2025 | 31% | +2.2 points |
| Q4 2024 | 30% | +14 points |
MS has the edge over DGICB on profitability, with a higher operating margin.
DGICB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $14.9M | -33% |
| Q2 2026 | $5.9M | -51% |
| Q1 2026 | $20.2M | -22% |
| Q4 2025 | $10M | -65% |
| Q3 2025 | $22.4M | +75% |
| Q2 2025 | $12.1M | -44% |
| Q1 2025 | $25.7M | +434% |
| Q4 2024 | $28.2M | +986% |
DGICB has the edge over MS on cash generation, producing positive trailing cash flow while its opponent burns cash.
MS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$46B | -$42.7B |
| Q2 2026 | -$2.7B | -123% |
| Q1 2026 | -$7.1B | +$16.9B |
| Q4 2025 | -$2.4B | -120% |
| Q3 2025 | -$3.3B | +$14B |
| Q2 2025 | $11.8B | +368% |
| Q1 2025 | -$24B | -650% |
| Q4 2024 | $11.8B | +$29.6B |
MS's free cash flow was −$58.3B over the past year, against −$3.7B the year before. Free cash flow isn't a meaningful measure for financial services companies like MS.
DGICB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.8% | +300K shares |
| 1 year | +2.1% | +778K shares |
| 3 years | +13% | +4.2M shares |
| 5 years | +19% | +6.1M shares |
| Available history | +30% | +8.6M shares |
DGICB has 37M diluted shares, up 2.1% from a year ago.
MS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -3M shares |
| 1 year | -1.5% | -24M shares |
| 3 years | -4.7% | -77M shares |
| 5 years | -14% | -246M shares |
| Available history | -4.5% | -74M shares |
MS has the edge over DGICB on shareholder dilution, with a more favorable share count trend.
DGICB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.0x | Very low |
| Q2 2026 | 0.1x | Very low |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | 0.1x | Very low |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.2x | Net Cash |
| Q1 2025 | -0.3x | Net Cash |
| Q4 2024 | -0.3x | Net Cash |
DGICB has the edge over MS on leverage, with a lower net debt burden relative to earnings.
MS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 7.8x | High |
| Q2 2026 | 7.3x | High |
| Q1 2026 | 8.2x | High |
| Q4 2025 | 8.6x | High |
| Q3 2025 | 8.4x | High |
| Q2 2025 | 8.7x | High |
| Q1 2025 | 8.7x | High |
| Q4 2024 | 7.9x | High |
MS's net debt is about 7.8 years of its operating earnings (EBITDA), down from 8.4 years a year ago. Net leverage isn't a meaningful measure for financial services companies like MS.
DGICB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.7 | Neutral |
| Stochastic | 90.7 | Overbought |
DGICB's weekly RSI is 65 (neutral) and its Stochastic is 91 (overbought).
MS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 18.7 | Oversold |
MS's weekly RSI is 45 (neutral) and its Stochastic is 19 (oversold).
DGICB PE vs Financial Services Sector
| Metric | DGICB | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 13x | 16% below |
| PE % | 46 | 63 | 17 pts below |
DGICB has the edge over MS on valuation relative to its sector.
MS PE vs Financial Services Sector
| Metric | MS | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 13x | 15% above |
| PE % | 59 | 63 | 4 pts below |
MS is trading at 15x earnings, a 15% premium to the Financial Services sector's median of 13x.
DGICB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $22.0 | 27% above |
| 20 week MA | $22.7 | 23% above |
| 50 week MA | $19.8 | 41% above |
| 100 week MA | $17.9 | 56% above |
| 200 week MA | $15.9 | 76% above |
DGICB has the edge over MS on trend strength, trading above more of its moving averages.
MS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $186.5 | 1.5% above |
| 20 week MA | $203.3 | 6.9% below |
| 50 week MA | $191.9 | 1.4% below |
| 100 week MA | $164.9 | 15% above |
| 200 week MA | $129.3 | 46% above |
MS's trend is mixed: it's above three of its five weekly moving averages, and 46% above its 200-week average.
DGICB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $12.1 | $12.2 | +0.7% |
| 2021 | $12.2 | $13.2 | +8.5% |
| 2022 | $13.2 | $17.9 | +35% |
| 2023 | $17.9 | $14.5 | -19% |
| 2024 | $14.5 | $14.7 | +1.2% |
| 2025 | $14.7 | $16.0 | +8.6% |
| 2026 YTD | $16.0 | $27.9 | +75% |
DGICB has the edge over MS on returns for 2026, with the stronger performance.
MS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.1 | $68.1 | +33% |
| 2021 | $68.1 | $99.3 | +46% |
| 2022 | $99.3 | $86.1 | -13% |
| 2023 | $86.1 | $93.3 | +8.3% |
| 2024 | $93.3 | $126.8 | +36% |
| 2025 | $126.8 | $181.9 | +43% |
| 2026 YTD | $181.9 | $189.2 | +4% |
MS has finished higher in five of the last six years. It's up 4% so far in 2026.